Systematic review on the role of serum tumor markers in the detection of recurrent pancreatic cancer

Daamen, Lois A; Groot, Vincent P.; Heerkens, H.D.; Intven, Martijn; Santvoort, Hjalmar C. van; Molenaar, I. Quintus

doi:10.1016/j.hpb.2017.11.009

Cited by 56 publications

(48 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, new methods are needed for early diagnosis and treatment of lung cancer bone metastasis [5,6]. The detection of serum tumor markers is safe with high e ciency, simple operation, and low price, which play an important role in the clinical diagnosis and treatment of cancer [7,8]. Chemokine is a class of secretory protein superfamily, which has chemotaxis and can regulate the adhesion and migration of leukocytes, lymphocytes and monocytes.…”

Section: Introductionmentioning

confidence: 99%

Clinical significance of expression level of CX3CL1–CX3CR1 axis in bone metastasis of lung cancer

Liu

Ma²,

Dong

et al. 2020

Clin Transl Oncol

View full text Add to dashboard Cite

Background: To investigate the clinical signi cance of CX3 chemokine ligand 1(CX3CL1) and CX3CR1 in patients with bone metastasis from lung cancer. The expression levels of CX3CL1 and CX3CR1 mRNA and protein in primary lung cancer and lung cancer bone metastasis were detected by qRT-PCR and Western blot. Methods: 100 patients with lung cancer were divided into a boneless metastasis group (50 patients with bone metastasis) and a bone metastasis group (50 patients without distant metastasis). The bone transfer component was graded by Soloway classi cation (0 to III). The expression levels of serum CX3CL1-CX3CR1 axis was detected by enzyme-linked immunosorbent assay (ELISA). RT-qPCR and Western Blot were used to verify the transfection e ciency. The scratching assay was used to detect the migration of CX3CL1 to 95-D cells after down-regulating the expression of CX3CR1. Results: The expression levels of CX3CL1 and CX3CR1 mRNA and protein in the primary lung cancer and lung cancer bone metastasis were signi cantly higher than those in the adjacent tissues (P<0.0001). The levels of serum CX3CL1 and CX3CR1 in bone metastasis group were signi cantly higher than those in boneless metastasis group and healthy control group (P<0.05). In the bone metastasis group, the levels of serum CX3CL1 and CX3CR1 was signi cantly positively correlated with the degree of disease progression (P<0.01). Conclusions: The expression level of serum CX3CL1-CX3CR1 axis is expected to be an auxiliary reference index for monitoring bone metastasis of lung cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical significance of expression level of CX3CL1–CX3CR1 axis in bone metastasis of lung cancer

Liu

Ma²,

Dong

et al. 2020

Clin Transl Oncol

View full text Add to dashboard Cite

show abstract

“…Furthermore, monitoring of disease recurrence after resection by testing biomarkers could be helpful in addition to imaging techniques such as CT, MRI or PET-CT [ 38 , 39 ]. CA 19-9 has been shown superior to CEA for monitoring of recurrence following radical resection of pancreatic cancer [ 40 ]. The results of this study could implicate that the MDT should consider neoadjuvant therapy in patients with elevated CA19-9 levels to achieve local downstaging in order to prevent patients from early recurrence and therefore unnecessary and high impact surgeries with long recovery times.…”

Section: Discussionmentioning

confidence: 99%

Stage-Specific Value of Carbohydrate Antigen 19-9 and Carcinoembryonic Antigen Serum Levels on Survival and Recurrence in Pancreatic Cancer: A Single Center Study and Meta-Analysis

Manen

Groen

Putter

et al. 2020

Cancers

View full text Add to dashboard Cite

This study aimed to determine the stage-specific prognostic value of carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) serum levels at diagnosis on overall survival (OS) and time to local recurrence or distant metastases in patients with pancreatic ductal adenocarcinoma (PDAC). Consecutive PDAC patients, discussed at multidisciplinary team meetings from 2013 through 2017, were reviewed. Prognostic factors were stage-specific (resection vs. advanced PDAC) evaluated in Cox proportional hazard models. Additionally, a systematic literature search and meta-analysis was performed, as current literature is lacking a complete overview of used cut-off values and the added value of CEA as prognostic marker. In the retrospective cohort, elevated CA19-9 (>305 kU/L) level was independently associated with poor OS (Hazard ratio (HR): 1.72(1.31–2.26)) and early recurrence (HR: 1.74(1.06–2.86)), whereas CEA was not significantly associated. The meta-analysis showed that both elevated CA19-9 and CEA serum levels were predictors for poor OS (pooled HR: 1.29(1.17–1.42) and HR: 1.51(1.33–1.73), respectively). In the resected cohort, elevated CA19-9 level was significantly associated with early recurrence (pooled HR: 2.41(1.77–3.29)), whereas CEA was not. Elevated CA19-9 serum level appear to be an independent prognostic factor for poor OS and early recurrence in PDAC patients, whereas the prognostic value of CEA is disputable.

show abstract

“…The massive focus on CA-19-9 and accompanying roller coaster emotions experienced by patients suggests a need to balance detection of cancer relapse with symptom management and rehabilitative interventions during follow-up [5]. Patients' needs for reassurance should be met with judicious heed to the lack of evidence for an effect on survival of regular follow-up after curatively intended treatment [2,3], the evidence indicating that CA-19-9 is a relatively unspecific marker for disease relapse [19], the poor prognosis even after curative surgery, and the fact there is no curative treatment option on recurrence [2,3]. Current ESMO guidelines call for increased attention to QOL and symptom management rather than detection of relapse [2,3].…”

Section: Discussionmentioning

confidence: 99%

It’s all about the CA-19-9. A longitudinal qualitative study of patients’ experiences and perspectives on follow-up after curative surgery for cancer in the pancreas, duodenum or bile-duct

et al. 2019

View full text Add to dashboard Cite

Background: Patients undergoing curative surgery for cancers of the pancreas, duodenum or bile ducts currently attend follow-up at specialized centers. Traditionally, follow-up after cancer has focused on cancer relapse. The Danish Health and Medicines Authority has recently pushed for a wider focus incorporating patients' individual needs and concerns during cancer rehabilitation. We aimed to explore patients' experiences of and perspectives on the rehabilitative scope of the current follow-up within the first year after curative treatment. Material and methods: A qualitative longitudinal design was undertaken with individual semi-structured interviews. We included twelve patients attending current follow-up after treatment for cancer in the pancreas, duodenum or bile-duct. We interviewed the patients three times over a period of 9 months. Data were analyzed longitudinally using inductive content analysis. Results: The patients experienced the cancer antigen (CA-19-9) as the center piece of follow-up, with consultations revolving largely around the CA-19-9 results. Parallel to and independent of follow-up, the patients described an array of creative strategies for adapting to their altered bodies and new life situation. The strategies included homemade endeavors to minimize gut symptoms, for example mint tablets or dairy products without lactose: realizing lifelong dreams and resolving financial matters; confiding with likeminded outside the family or professionals outside the hospital. First encounters with HCPs were critically important with bad first encounters haunting patients throughout follow-up and good first encounters facilitating trust and reciprocity between patients and HCPs. Conclusion: Patients in this study perceived detection of relapse through CA-19-9 as the focal point of follow-up, leaving other patient-important symptoms insufficiently addressed. We may, therefore, consider not using this relatively unprecise marker for relapse in the future. Balancing clinicians' needs to diagnose relapse with patients' needs for rehabilitation warrants attention in clinical practice and future research.

show abstract

Systematic review on the role of serum tumor markers in the detection of recurrent pancreatic cancer

Cited by 56 publications

References 54 publications

Clinical significance of expression level of CX3CL1–CX3CR1 axis in bone metastasis of lung cancer

Clinical significance of expression level of CX3CL1–CX3CR1 axis in bone metastasis of lung cancer

Stage-Specific Value of Carbohydrate Antigen 19-9 and Carcinoembryonic Antigen Serum Levels on Survival and Recurrence in Pancreatic Cancer: A Single Center Study and Meta-Analysis

It’s all about the CA-19-9. A longitudinal qualitative study of patients’ experiences and perspectives on follow-up after curative surgery for cancer in the pancreas, duodenum or bile-duct

Contact Info

Product

Resources

About